Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HAE Haemonetics Corp
- Stocks
- Healthcare
- NYSE: HAE
Price (delayed)
$68.65
Market cap
$3.45B
P/E Ratio
26.82
Dividend/share
N/A
EPS
$2.56
Enterprise value
$4.35B
Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of
Highlights
The price to earnings (P/E) is 49% lower than the 5-year quarterly average of 52.4 and 21% lower than the last 4 quarters average of 34.1
The company's quick ratio rose by 35% YoY and by 12% QoQ
The equity has declined by 3.9% year-on-year but it is up by 3.2% since the previous quarter
The debt is up by 41% year-on-year
Key stats
What are the main financial stats of HAE
Market
Valuations
Earnings
Shares outstanding
50.24M
Market cap
$3.45B
Enterprise value
$4.35B
Price to earnings (P/E)
26.82
Price to book (P/B)
3.8
Price to sales (P/S)
2.51
EV/EBIT
24.13
EV/EBITDA
14.73
EV/Sales
3.17
Revenue
$1.37B
Gross profit
$731.81M
Operating income
$180.43M
Net income
$130.07M
EBIT
$180.43M
EBITDA
$295.44M
Free cash flow
$104.63M
Per share
Balance sheet
Liquidity
EPS
$2.56
EPS diluted
$2.54
Free cash flow per share
$2.08
Book value per share
$18.06
Revenue per share
$27.31
TBVPS
$29.04
Total assets
$2.53B
Total liabilities
$1.62B
Debt
$1.22B
Equity
$906.86M
Working capital
$752.64M
Debt to equity
1.35
Current ratio
3.97
Quick ratio
2.1
Net debt/EBITDA
3.06
Margins
Efficiency
Dividend
EBITDA margin
21.5%
Gross margin
53.3%
Net margin
9.5%
Operating margin
13.1%
Return on assets
5.3%
Return on equity
14.2%
Return on invested capital
9.3%
Return on capital employed
7.9%
Return on sales
13.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HAE stock price
How has the Haemonetics stock price performed over time
Intraday
-0.71%
1 week
6.85%
1 month
15.53%
1 year
-29.5%
YTD
-12.08%
QTD
8.03%
Financial performance
How have Haemonetics's revenue and profit performed over time
Revenue
$1.37B
Gross profit
$731.81M
Operating income
$180.43M
Net income
$130.07M
Gross margin
53.3%
Net margin
9.5%
The company's gross profit rose by 9% YoY and by 2.2% QoQ
The operating income is up by 8% since the previous quarter and by 6% year-on-year
The revenue rose by 8% YoY
The operating margin has grown by 7% from the previous quarter but it has contracted by 2.2% YoY
Price vs fundamentals
How does HAE's price correlate with its fundamentals
Growth
What is Haemonetics's growth rate over time
Valuation
What is Haemonetics stock price valuation
P/E
26.82
P/B
3.8
P/S
2.51
EV/EBIT
24.13
EV/EBITDA
14.73
EV/Sales
3.17
The price to earnings (P/E) is 49% lower than the 5-year quarterly average of 52.4 and 21% lower than the last 4 quarters average of 34.1
The company's EPS rose by 5% QoQ and by 2.4% YoY
The price to book (P/B) is 28% lower than the 5-year quarterly average of 5.3 and 16% lower than the last 4 quarters average of 4.5
The equity has declined by 3.9% year-on-year but it is up by 3.2% since the previous quarter
The stock's P/S is 36% less than its 5-year quarterly average of 3.9 and 19% less than its last 4 quarters average of 3.1
The revenue rose by 8% YoY
Efficiency
How efficient is Haemonetics business performance
The company's return on invested capital fell by 18% YoY
The company's return on assets fell by 15% YoY
The company's return on sales rose by 7% QoQ but it fell by 2.2% YoY
HAE's return on equity is up by 6% since the previous quarter
Dividends
What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HAE.
Financial health
How did Haemonetics financials performed over time
The total assets is 56% more than the total liabilities
The current ratio has grown by 36% YoY and by 14% from the previous quarter
The company's quick ratio rose by 35% YoY and by 12% QoQ
The debt is 35% greater than the equity
The debt to equity has grown by 47% YoY but it has contracted by 2.9% from the previous quarter
The debt is up by 41% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.